US Stock Market Move | Bristol-Myers Squibb Company (BMY.US) rises by 5%. The company will continue researching Alzheimer's disease.

On Wednesday, Bristol-Myers Squibb Company (BMY.US) rose by 5% to $50.67. On the news front, Shire announced on Wednesday that they will recruit more participants for a late-stage trial to evaluate the safety and efficacy of Cobenfy in treating Alzheimer's disease-related dementia psychosis. The company stated that this decision was made after discovering some trial sites engaged in "protocol deviations" related to clinical study conduct, and the patient data from these sites will be excluded from the primary analysis. It is understood that Cobenfy is currently approved for the treatment of adult schizophrenia, with the potential to become the first new class of drug therapy targeting agitation and psychosis based on its muscarinic receptor agonist action. It is expected that the results of other trials targeting Alzheimer's disease-related psychosis under the ADEPT program (including ADEPT-2, ADEPT-1, and ADEPT-4) will be disclosed by the end of 2026.